A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

NCT00264732 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

251

Enrollment

INDUSTRY

Sponsor class

Conditions

Uterine Cervical Dysplasia

Interventions

DRUG: Amolimogene
DRUG: Amolimogene
OTHER: Placebo

Sponsor

Eisai Inc.